Jaume Alijotas Reig Instituciones de las que forman parte Jefe de grupo Enfermedades Sistémicas Vall Hebron Institut de Recerca Email Jaume Alijotas Reig Email Instituciones de las que forman parte Jefe de grupo Enfermedades Sistémicas Vall Hebron Institut de Recerca
Líneas de investigación Predictive kit to detect the possible establishment of late adverse effects related to bioimplants used in clinical practice. A high variability in the prevalence of adverse effects with an immunologic basis seems to be related with any implant used in clinical practice. We have managed to find a particular association of HLA haplotypes that increase the risk for developing these effects up to 600 times. We are nowadays working on setting up a safe and reliable biochip or kit which predicts this risk easily in a routine test. IP: Jaume Alijotas Reig Immunobiology and immunopathology of recurrent pregnancy loses and spontaneous loses. Around 2-3% of reproductive-age couples suffer recurrent pregnancy loses. Almost 18% of couples that wish to have children suffer infertility problems. Simultaneously, 2-3% of all pregnant women are diagnosed with spontaneous loses. The expression of HLA molecules, specially type G, the degree of trophoblastic apoptosis, the outsourcing of new neoantigens such as phospholipids, the balance between Th1/Th2/Th3 cytokines, the type and quantity of CD4+CD25+Foxp3+ lymphocytes, the kind and the activity of uterine NK cells (uNK) cells, the presence or absence of blocking antibodies, and other mechanisms play different roles in the achievement of the so-called "tolerant microenvironment" needed to develop a normal pregnancy. Therefore, both autoimmune and alloimmune mechanisms are important. We aim at studying which isolated, and specially associated, anomalies can be identified as risk markers to be able to evaluate possible treatments. IP: Jaume Alijotas Reig Paginación Primera página « Página anterior ‹ Página 1 Página 2 Página actual 3 Proyectos Envejecimiento endotelial y sus efectos pleiotrópicos sobre procesos inflamatorios, de la respuesta inmune y angiogénesis IP: Francesc Miro Mur Colaboradores: Jaume Alijotas Reig, Simon Schwartz Navarro Entidad financiadora: Fundación Invest. Médica Mutua Madrileña Financiación: 36000 Referencia: FMMA/05/2008 Duración: 24/09/2008 - 23/09/2011 CIBER: Bioingenieria, biomateriales y nanomedicina IP: - Colaboradores: CIBER: Bioingenieria, biomateriales y nanomedicina, Manuel López Cano, Jaume Alijotas Reig, Francesc Miro Mur, Eloy Espín Basany, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina, CIBER: Bioingenieria, biomateriales y nanomedicina Entidad financiadora: CIBER Bioing., Biomateriales y Nanomedicina , BBN Financiación: 480000 Referencia: CB06/01/0012 Duración: 01/01/2007 - 31/12/2010 Paginación Primera página « Página anterior ‹ Página 1 Página 2 Página actual 3
